We have collected information about Oligonucleotide Delivery In Cancer Therapy for you. Follow the links to find out details on Oligonucleotide Delivery In Cancer Therapy.
https://www.researchgate.net/publication/47555145_Oligonucleotide_delivery_in_cancer_therapy
Oligonucleotide delivery in cancer therapy Article · Literature Review (PDF Available) in Expert Opinion on Drug Delivery 7(11):1263-78 · November 2010 with 104 Reads How we measure 'reads'
https://www.nature.com/articles/1207231
As a result, there is still a large unmet medical need to identify and develop better therapeutics for the treatment of cancer. Antisense oligonucleotides represent a potential solution to some of ...
https://www.optcongress.com/oligonucleotide
CHI’s Oligonucleotide Discovery and Delivery conference reveals the latest strategies at the forefront of discovery, chemistry and delivery with in-depth sessions on new chemistries, novel delivery mechanisms and the most important preclinical and clinical advances.
https://www.nature.com/articles/nrc1631
May 20, 2005 · Antisense oligonucleotides (ASOs) offer one approach to target genes involved in cancer progression, particularly those that are not amenable to small-molecule or antibody inhibition.
https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0545-9
Mar 12, 2019 · Cancer cells are known to develop mechanisms to circumvent effective anti-tumor immunity. The two ectonucleotidases CD39 and CD73 are promising drug targets, as they act in concert to convert extracellular immune-stimulating ATP to adenosine. CD39 is expressed by different immune cell populations as well as cancer cells of different tumor types and supports the tumor in escaping …
https://csce.ucmss.com/cr/books/2017/LFS/CSREA2017/BIE3506.pdf
Drug Delivery for Colon Cancer Therapy by Doxorubicin with Oligonucleotide modified Gold-nanoparticles Moo-Jun Baek, Dongjun Jeong, Hyung Ju Kim Department of Surgery, College of Medicine Soonchunhyang University, Cheonan, Korea Abstract-The major problem associated with chemotherapy is the inability to deliver pharmaceuticals to specific site ...
https://advances.sciencemag.org/content/4/10/eaat3386.full
Antisense oligonucleotide (ASO) silencing of the expression of disease-associated genes is an attractive novel therapeutic approach, but treatments are limited by the ability to deliver ASOs to cells and tissues. Following systemic administration, ASOs preferentially accumulate in liver and kidney. Among the cell types refractory to ASO uptake is the pancreatic insulin-secreting β-cell. Here ...
https://www.intechopen.com/online-first/antisense-oligonucleotides-a-novel-developing-targeting-therapy
To bypass the limitations of ASO-based therapy, like insufficient stability and low intracellular delivery and distribution, Dr. Rocchi’s lab recently developed a modified first-generation ASO by using a lipid-conjugated oligonucleotide modification (LASO) able to overcome the problems to ASO administration.
https://www.sciencedirect.com/topics/neuroscience/antisense-oligonucleotide
Both of these delivery systems will then deliver the genetic material to the cell as described in the previous sections. The stability of oligonucleotides once in the cell is another limiting aspect to ASO therapy. Oligonucleotides are very sensitive to degradation by exogenous and endogenous nucleases.
https://www.sciencedirect.com/science/article/pii/S1818087614000646
The currently developed siRNA delivery systems for cancer therapy can be divided into four categories: chemical modifications, lipid-based nanovectors, polymer-mediated delivery systems, conjugate delivery systems, and others (exosomes, RNAi-microsponges, oligonucleotide nanoparticles). 4.1. Chemical modifications of anti-cancer siRNA
https://onlinelibrary.wiley.com/doi/abs/10.1002/adma.201606134
Mar 29, 2017 · Metal–Organic Framework (MOF)‐Based Drug/Cargo Delivery and Cancer Therapy. Ming‐Xue Wu. International Joint Research Laboratory of Nano‐Micro Architecture Chemistry (NMAC), College of Chemistry, Jilin University, 2699 Qianjin Street, Changchun, 130012 China. Search for more papers by this author.
https://www.ncbi.nlm.nih.gov/pubmed/27102380
Oligonucleotide-based theranostic nanoparticles in cancer therapy. Shahbazi R(1), Ozpolat B(2), Ulubayram K(1)(3)(4). Author information: (1)Department of Nanotechnology & Nanomedicine, Institute for Graduate Studies in Science & Engineering, Hacettepe University, Ankara 06532, Turkey.
https://www.sciencedirect.com/science/article/pii/S0169409X02000467
The first section of this review provides an overview of the most frequently used cationic polymers in non-viral gene and oligonucleotide delivery. Since the inefficiency of these vectors in (cancer) gene therapy can be attributed to specific hurdles on a systemic, as well as subcellular level, strategies to surmount these will be discussed.
https://www.genengnews.com/topics/drug-discovery/oligonucleotide-nanostructure-targets-cancer-cells-for-rna-therapy/
Aug 14, 2018 · The delivery of therapies specifically to cancer cells has always been hindered by limitations of the delivery molecules—all too often off-target effects can be detrimental to a patient’s ...
https://en.wikipedia.org/wiki/Antisense_therapy
Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to cause a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene "off".
Searching for Oligonucleotide Delivery In Cancer Therapy?
You can just click the links above. The data is collected for you.
